Discovery: Use of Systems Biology for Identifying Targets

In our introduction, we emphasized that a combination of reductionist (mechanism-based) and holistic (hypothesis-based) tools in the drug screening process may increase the efficiency of overall Drug Discovery. Among notable holistic tools are screens that target discovery and characterization of molecular probes (compounds) that will enable the investigation of fundamental biological function at molecular, cellular and whole organism levels. Such screening usually occurs at the earlier stages of drug discovery.

[1]  L. Rychlewski,et al.  Meta-basic estimates the size of druggable human genome , 2009, Journal of molecular modeling.

[2]  Christoph M Huwe,et al.  Synthetic library design. , 2006, Drug discovery today.

[3]  Pierre Baldi,et al.  ChemDB update - full-text search and virtual chemical space , 2007, Bioinform..

[4]  Peter Ertl,et al.  Cheminformatics Analysis of Organic Substituents: Identification of the Most Common Substituents, Calculation of Substituent Properties, and Automatic Identification of Drug-like Bioisosteric Groups , 2003, J. Chem. Inf. Comput. Sci..

[5]  Dora M Schnur.  Recent trends in library design: 'rational design' revisited. , 2008, Current opinion in drug discovery & development.

[6]  Stefan H. Unger,et al.  Model building in structure-activity relations. Reexamination of adrenergic blocking activity of .beta.-halo-.beta.-arylalkylamines , 1973 .

[7]  P. Hajduk,et al.  Predicting protein druggability. , 2005, Drug discovery today.

[8]  S. Wetzel,et al.  Biology-inspired synthesis of compound libraries , 2008, Cellular and Molecular Life Sciences.

[9]  D. Fattori,et al.  Fragment-Based Approach to Drug Lead Discovery , 2008, Drugs in R&D.

[10]  Alexander Golbraikh,et al.  Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.

[11]  Andrew J. Doig,et al.  Properties and identification of human protein drug targets , 2009, Bioinform..

[12]  Andrew R Leach,et al.  Fragment screening: an introduction. , 2006, Molecular bioSystems.

[13]  Zhaolei Zhang,et al.  Experimental and computational procedures for the assessment of protein complexes on a genome-wide scale. , 2007, Chemical reviews.

[14]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[15]  A. Hopfinger,et al.  Methods for applying the quantitative structure-activity relationship paradigm. , 2004, Methods in molecular biology.

[16]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[17]  Pierre Acklin,et al.  Similarity Metrics for Ligands Reflecting the Similarity of the Target Proteins , 2003, J. Chem. Inf. Comput. Sci..

[18]  Roland E. Dolle,et al.  Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2007. , 2008, Journal of combinatorial chemistry.

[19]  Adriano D Andricopulo,et al.  Hologram QSAR model for the prediction of human oral bioavailability. , 2007, Bioorganic & medicinal chemistry.

[20]  Xiang-Qun Xie,et al.  Data Mining a Small Molecule Drug Screening Representative Subset from NIH PubChem , 2008, J. Chem. Inf. Model..

[21]  J. Drews.  Intent and coincidence in pharmaceutical discovery. The impact of biotechnology. , 1995, Arzneimittel-Forschung.

[22]  C. Bewley,et al.  Synthetic macrolides that inhibit breast cancer cell migration in vitro. , 2007, Journal of the American Chemical Society.

[23]  Brent R Stockwell,et al.  Identifying druggable disease-modifying gene products. , 2009, Current opinion in chemical biology.

[24]  Wei Zhang,et al.  Recent advances in computational prediction of drug absorption and permeability in drug discovery. , 2006, Current medicinal chemistry.

[25]  D. Erlanson.  Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[26]  Vladimir Potemkin,et al.  Principles for 3D/4D QSAR classification of drugs. , 2008, Drug discovery today.

[27]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[28]  D. Burke,et al.  Chirality: a blueprint for the future. , 2002, British journal of anaesthesia.

[29]  L. A. Marcaurelle,et al.  Application of natural product-inspired diversity-oriented synthesis to drug discovery. , 2008, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[30]  H Matter,et al.  Computational approaches towards the rational design of drug-like compound libraries. , 2001, Combinatorial chemistry & high throughput screening.

[31]  J. Drews.  Stategic trends in the drug industry. , 2003, Drug discovery today.

[32]  S H Unger,et al.  On model building in structure-activity relationships. A reexamination of adrenergic blocking activity of beta-halo-beta-arylalkylamines. , 1973, Journal of medicinal chemistry.

[33]  Wei Zhang,et al.  Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2007. , 2008, Journal of combinatorial chemistry.

[34]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.